Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

Deok Hwan Yang, Je Jung Lee, Yeung Chul Mun, Ho Jin Shin, Yeo Kyeoung Kim, Sang Hee Cho, Ik Joo Chung, Chu Myong Seong, Hyeoung Joon Kim

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease-free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56- group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56- group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the C056+ patients was significantly shorter than the CD56- patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalAmerican Journal of Hematology
Volume82
Issue number1
DOIs
StatePublished - Jan 2007

Keywords

  • Allogeneic stem cell transplantation
  • AML with t(8;21)
  • CD56 expression
  • Disease-free survival
  • Prognostic significance
  • Survival

Fingerprint

Dive into the research topics of 'Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this